
Photo: Mint
Business & Finance
Why Indian drugmakers are losing pricing power in the US
TL;DR
- Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 17, 2026 · Updated 11/17/2026, 5:08:27 AM · Reported with: Mint
Sources (1)
NRI Bytes writes its own articles from the reporting below.
Mint — Why Indian drugmakers are losing pricing power in the USUp next · Business & Finance
Paint Companies Announce Second Round Of November Price Hikes As Costs Rise | Profit Exclusive
Read next →
More stories

Business & Finance
Who Is Madison Huang? Meet Jensen Huang's Daughter, Her Nvidia Role And Equation With Interim CEO
44m ago

Business & Finance
'Bhagwan Ko Bhi Saath Jod Liya': Ayurvedic Healthcare Firm Awaits Ayushman Scheme
44m ago

Business & Finance
Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery
44m ago

Business & Finance
Why Only Go After Big Names? X User Reacts To FDA’s Action On Vaishali And Rupali Hotels, Sparks Debate
44m ago


